Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity

References

• Ahn KH, Mahmoud MM, Kendall DA. 2012. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. J Biol Chem. 287:12070–12082.
   PubMed Web of Science ®Google Scholar
• Ahn KH, Mahmoud MM, Samala S, Lu D, Kendall DA. 2013. Profiling two indole-2-carboxamides for allosteric modulation of the CB1 receptor. J Neurochem. 124:584–589.
   PubMed Web of Science ®Google Scholar
• Ahn KH, Mahmoud MM, Shim J-Y, Kendall DA. 2013. Distinct roles of β-arrestin 1 and β-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1). J Biol Chem. 288:9790–9800.
   PubMed Web of Science ®Google Scholar
• Bauer M, Chicca A, Tamborrini M, Eisen D, Lerner R, Lutz B, Poetz O, Pluschke G, Gertsch J. 2012. Identification and quantification of a new family of peptide endocannabinoids (pepcans) showing negative allosteric modulation at CB1 receptors. J Biol Chem. 287:36944–36967.
   PubMed Web of Science ®Google Scholar
• Bertini S, Chicca A, Gado F, Arena C, Nieri D, Digiacomo M, Saccomanni G, Zhao P, Abood ME, Macchia M. 2017. Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor. Bioorg Med Chem. 25:6427–6434.
   PubMed Web of Science ®Google Scholar
• Burford N, Traynor J, Alt A. 2015. Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications. Br J Pharmacol. 172:277–286.
   PubMed Web of Science ®Google Scholar
• Christopoulos A, Kenakin T. 2002. G protein-coupled receptor allosterism and complexing. Pharmacol Rev. 54:323–374.
   PubMed Web of Science ®Google Scholar
• Conn PJ, Christopoulos A, Lindsley CW. 2009. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov. 8:41–54.
   PubMed Web of Science ®Google Scholar
• Ding Y, Qiu Y, Jing L, Thorn DA, Zhang Y, Li JX. 2014. Behavioral effects of the cannabinoid CB1 receptor allosteric modulator ORG27569 in rats. Pharmacol Res Perspect. 2:1–11.
   Google Scholar
• Donvito G, Nass SR, Wilkerson JL, Curry ZA, Schurman LD, Kinsey SG, Lichtman AH. 2017. The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain. Neuropsychopharmacology. 43:52–79.
   PubMed Web of Science ®Google Scholar
• Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, et al. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 49:4721–4732.
   PubMed Web of Science ®Google Scholar
• Fay JF, Farrens DL. 2013. The membrane proximal region of the cannabinoid receptor CB1 N-terminus can allosterically modulate ligand affinity. Biochemistry. 52:8286–8294.
   PubMed Web of Science ®Google Scholar
• Fernández-Ruiz J, Romero J, Ramos JA. 2015. Endocannabinoids and neurodegenerative disorders: Parkinson's disease, Huntington's chorea, Alzheimer's disease, and others. Handb Exp Pharmacol. 231:233–259.
   Google Scholar
• Gamage TF, Farquhar CE, Lefever TW, Thomas BF, Nguyen T, Zhang Y, Wiley JL. 2017. The great divide: separation between in vitro and in vivo effects of PSNCBAM-based CB1 receptor allosteric modulators. Neuropharmacology. 125:365–375.
   PubMed Web of Science ®Google Scholar
• Gamage TF, Ignatowska-Jankowska BM, Wiley JL, Abdelrahman M, Trembleau L, Greig IR, Thakur GA, Tichkule R, Poklis J, Ross RA. 2014. In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. Behav Pharmacol. 25:182.
   PubMed Web of Science ®Google Scholar
• Gao Z-G, Jacobson KA. 2013. Allosteric modulation and functional selectivity of G protein-coupled receptors. Drug Discov Today: Technol. 10:237–243.
   PubMedGoogle Scholar
• Gentry PR, Sexton PM, Christopoulos A. 2015. Novel allosteric modulators of G protein-coupled receptors. J Biol Chem. 290:19478–19488.
   PubMed Web of Science ®Google Scholar
• German N, Decker AM, Gilmour BP, Gay EA, Wiley JL, Thomas BF, Zhang Y. 2014. Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure–activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl) pyridin-2-yl] phenyl} urea (PSNCBAM-1). J Med Chem. 57:7758–7769.
   PubMed Web of Science ®Google Scholar
• Gregory KJ, Noetzel MJ, Niswender CM. 2013. Pharmacology of metabotropic glutamate receptor allosteric modulators: structural basis and therapeutic potential for CNS disorders. Prog Mol Biol Transl Sci. 115:61–121.
   Google Scholar
• Gregory KJ, Valant C, Simms J, Sexton PM, Christopoulos A. 2010. The emergence of allosteric modulators for G protein-coupled receptors. In: Gilchrist A, editor. GPCR molecular pharmacology and drug targeting: shifting paradigms and new directions. New York: John Wiley; p. 61–87.
   Google Scholar
• Harrington PE, Fotsch C. 2007. Calcium sensing receptor activators: calcimimetics. Curr Med Chem. 14:3027–3034.
   PubMed Web of Science ®Google Scholar
• Horswill J, Bali U, Shaaban S, Keily J, Jeevaratnam P, Babbs A, Reynet C, Wong Kai In P. 2007. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol. 152:805–814.
   PubMed Web of Science ®Google Scholar
• Hua T, Vemuri K, Nikas SP, Laprairie RB, Wu Y, Qu L, Pu M, Korde A, Jiang S, Ho J-H. 2017. Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature. 547:468–471.
   PubMed Web of Science ®Google Scholar
• Hua T, Vemuri K, Pu M, Qu L, Han GW, Wu Y, Zhao S, Shui W, Li S, Korde A. 2016. Crystal structure of the human cannabinoid receptor CB 1. Cell. 167:750–762.
   PubMed Web of Science ®Google Scholar
• Ignatowska-Jankowska BM, Baillie GL, Kinsey S, Crowe M, Ghosh S, Owens RA, Damaj IM, Poklis J, Wiley JL, Zanda M. 2015. A cannabinoid CB1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects. Neuropsychopharmacology. 40:2948–2959.
   PubMed Web of Science ®Google Scholar
• Jing L, Qiu Y, Zhang Y, Li J-X. 2014. Effects of the cannabinoid CBI receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and methamphetamine-seeking behavior in rats. Drug Alcohol Depend. 143:251–256.
   PubMed Web of Science ®Google Scholar
• Khurana L, Ali HI, Olszewska T, Ahn KH, Damaraju A, Kendall DA, Lu D. 2014. Optimization of chemical functionalities of indole-2-carboxamides to improve allosteric parameters for the cannabinoid receptor 1 (CB1). J Med Chem. 57:3040–3052.
   PubMed Web of Science ®Google Scholar
• Khurana L, Fu B-Q, Duddupudi AL, Liao Y-H, Immadi SS, Kendall DA, Lu D. 2017. Pyrimidinyl biphenylureas: identification of new lead compounds as allosteric modulators of the cannabinoid receptor CB1. J Med Chem. 60:1089–1104.
   PubMed Web of Science ®Google Scholar
• Kulkarni PM, Kulkarni AR, Korde A, Tichkule RB, Laprairie RB, Denovan-Wright EM, Zhou H, Janero DR, Zvonok N, Makriyannis A. 2015. Novel electrophilic and photoaffinity covalent probes for mapping the cannabinoid 1 receptor allosteric site(s). J Med Chem. 59:44–60.
   PubMed Web of Science ®Google Scholar
• Laprairie RB, Kulkarni PM, Deschamps JR, Kelly ME, Janero DR, Cascio MG, Stevenson LA, Pertwee RG, Kenakin TP, Denovan-Wright EM. 2017. Enantiospecific allosteric modulation of cannabinoid 1 receptor. ACS Chem Neurosci. 8:1188–1203.
   PubMed Web of Science ®Google Scholar
• Leterrier C, Bonnard D, Carrel D, Rossier J, Lenkei Z. 2004. Constitutive endocytic cycle of the CB1 cannabinoid receptor. J Biol Chem. 279:36013–36021.
   PubMed Web of Science ®Google Scholar
• Mahmoud MM, Ali HI, Ahn KH, Damaraju A, Samala S, Pulipati VK, Kolluru S, Kendall DA, Lu D. 2013. Structure–activity relationship study of indole-2-carboxamides identifies a potent allosteric modulator for the cannabinoid receptor 1 (CB1). J Med Chem. 56:7965–7975.
   PubMed Web of Science ®Google Scholar
• Maldonado R, Valverde O, Berrendero F. 2006. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 29:225–232.
   PubMed Web of Science ®Google Scholar
• Navarro HA, Howard JL, Pollard GT, Carroll F. 2009. Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br J Pharmacol. 156:1178–1184.
   PubMed Web of Science ®Google Scholar
• Nguyen T, German N, Decker AM, Langston TL, Gamage TF, Farquhar CE, Li J-X, Wiley JL, Thomas BF, Zhang Y. 2017. Novel diarylurea based allosteric modulators of the cannabinoid CB1 receptor: evaluation of importance of 6-pyrrolidinylpyridinyl substitution. J Med Chem. 60:7410–7424.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Li JX, Thomas BF, Wiley JL, Kenakin TP, Zhang Y. 2016. Allosteric modulation: an alternate approach targeting the cannabinoid CB1 receptor. Med Res Rev. 37:441–474.
   PubMed Web of Science ®Google Scholar
• Pamplona FA, Ferreira J, de Lima OM, Duarte FS, Bento AF, Forner S, Villarinho JG, Bellocchio L, Wotjak CT, Lerner R. 2012. Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc Natl Acad Sci. 109:21134–21139.
   PubMed Web of Science ®Google Scholar
• Pertwee RG. 2008. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol. 13:147–159.
   PubMed Web of Science ®Google Scholar
• Piscitelli F, Ligresti A, La Regina G, Coluccia A, Morera L, Allarà M, Novellino E, Di Marzo V, Silvestri R. 2012. Indole-2-carboxamides as allosteric modulators of the cannabinoid CB1 receptor. J Med Chem. 55:5627–5631.
   PubMed Web of Science ®Google Scholar
• Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A, McIntosh L, Goodwin G, Walker G, et al. 2005. Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol. 68:1484–1495.
   PubMed Web of Science ®Google Scholar
• Qiao C-J, Ali HI, Ahn KH, Kolluru S, Kendall DA, Lu D. 2016. Synthesis and biological evaluation of indole-2-carboxamides bearing photoactivatable functionalities as novel allosteric modulators for the cannabinoid CB1 receptor. Eur J Med Chem. 121:517–529.
   PubMed Web of Science ®Google Scholar
• Schwartz TW, Holst B. 2006. Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. J Receptors Signal Transduct. 26:107–128.
   PubMed Web of Science ®Google Scholar
• Schwartz TW, Holst B. 2007. Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act? Trends Pharmacol Sci. 28:366–373.
   PubMed Web of Science ®Google Scholar
• Shao Z, Yin J, Chapman K, Grzemska M, Clark L, Wang J, Rosenbaum DM. 2016. High-resolution crystal structure of the human CB1 cannabinoid receptor. Nature. 540:602–606.
   PubMed Web of Science ®Google Scholar
• Shore DM, Baillie GL, Hurst DH, Navas F, Seltzman HH, Marcu JP, Abood ME, Ross RA, Reggio PH. 2014. Allosteric modulation of a cannabinoid G protein-coupled receptor binding site elucidation and relationship to G protein signaling. J Biol Chem. 289:5828–5845.
   PubMed Web of Science ®Google Scholar
• Silvestri C, Di Marzo V. 2013. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab. 17:475–490.
   PubMed Web of Science ®Google Scholar
• Simon V, Cota D. 2017. Mechanism in endocrinology: endocannabinoids and metabolism: past, present and future. Eur J Endocrinol. 176:309–324.
   Web of Science ®Google Scholar
• Slivicki RA, Xu Z, Kulkarni PM, Pertwee RG, Mackie K, Thakur GA, Hohmann AG. 2017. Positive allosteric modulation of cannabinoid receptor type 1 suppresses pathological pain without producing tolerance or dependence. Biol Psychiatry. [accessed 2017 November 7]:[12 p.]. doi: 10.1016/j.biopsych2017.06.032.
   PubMed Web of Science ®Google Scholar
• Smith TH, Sim‐Selley LJ, Selley DE. 2010. Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br J Pharmacol. 160:454–466.
   PubMed Web of Science ®Google Scholar
• Stornaiuolo M, Bruno A, Botta L, La Regina G, Cosconati S, Silvestri R, Marinelli L, Novellino E. 2015. Endogenous vs exogenous allosteric modulators in GPCRs: a dispute for shuttling CB1 among different membrane microenvironments. Sci Rep. 5:15453.
   PubMed Web of Science ®Google Scholar
• Wang X, Horswill JG, Whalley BJ, Stephens GJ. 2011. Effects of the allosteric antagonist 1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum. Mol Pharmacol. 79:758–767.
   PubMed Web of Science ®Google Scholar
• Woodhams SG, Chapman V, Finn DP, Hohmann AG, Neugebauer V. 2017. The cannabinoid system and pain. Neuropharmacology. 124:105–120.
   PubMed Web of Science ®Google Scholar